Victoria Socha

DocwireNews

American Transplant Congress 2021Heart allograft allocation is the primary determinant for heart-kidney transplantation (HKT) in the United States. S. Rao and colleagues conducted an analysis of the Organ Procurement and Transplantation Network (OPTN) database to compare outcomes of HKT performed under the former heart allocation system (prior-HAS, October 1, 2015-October 18, 2018, n=516) and under the current HAS that prioritizes sicker patients (after October 18, 2018, n=149).The researchers reported results of the analysis during a virtual presentation at the 2021 American Transplant Congress. The presentation was titled Early Outcome of Heart-Kidney Transplantation in the Current Heart Allocation System in the United States.The analysis included de-identified data from the OPTN registry with follow-up through December 6, 2019. Data included baseline demographics, comorbidities, and the etiology of cardiac and kidney dysfunction. Inotropic and/or mechanical circulatory support were used to assess pretransplant cardiac support. Serum creatinine level at listing, the need for pretransplant dialysis, and duration of dialysis (short &le;6 weeks, medium 7-12 weeks, and long &gt;12 weeks) were used to assess kidney dysfunction pretransplant.The percentage of HKT among total heart <a href="https://www.docwirenews.com/nephtimes/midodrine-use-in-patients-undergoing-simultaneous-liver-kidney-transplantation/">transplants</a> has increased from 5.3% in the prior-HAS era to 6.4% under the current HAS (P=.038). While the prevalence of pretransplant dialysis was similar between the two groups (~50%), a higher percentage in the current-HAS group were in the short dialysis duration group (24.5% vs 7.3%; P=.01).Results of univariate Cox regression analysis demonstrated lower 180-day survival in the current-HAS group (87.2% vs 92.4%; hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.01-3.04; P=.04) and a trend toward lower kidney allograft survival (83.9% vs 85.9%; HR, 1.60; 95% CI, 0.09-2.59; P=.05). Following adjustment for covariates, the HAS era was not an independent predictor of outcomes. Delayed graft function of kidney allograft remained a strong predictor of poorer outcomes and was higher in the current-HAS group (35% vs 26%, P=.03).In conclusion, the researchers said, &ldquo;Our study shows that the rates of HKT have continued to increase under the current HAS. Similar to the higher mortality in heart transplant recipients under the current-HAS era, patient mortality was higher in the HKT recipients too. This study highlights the need for a novel HKT allocation policy with standardized listing and allocation criteria aimed to improve HKT outcomes.&rdquo;Source: Rao S, Doyle A, Brennan D, Constantinescu S. Early outcome of heart-kidney transplantation in the current heart allocation system in the United States. Abstract of a presentation at the virtual American Transplant Congress 2021 (abstract #413), June 6, 2021.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Outcomes in HKT after Change in Allocation System

American Transplant Congress 2021

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe